Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates


– First patient dosed with STK-001 in Part A of Phase 1/2a MONARCH clinical trial for Dravet syndrome –

– Company on track to identify an additional pre-clinical candidate derived from its TANGO platform for the treatment of an additional genetic disease in 2H 2020 –

– As of June 30, 2020, company has $202.1 million in cash, cash equivalents and restricted cash, anticipated to fund operations into 2023 –

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for

Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights


PALO ALTO, Calif., Aug. 10, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the second quarter ended June 30, 2020.

“We have made strong progress across the entire company this quarter— clinical, manufacturing, research and corporate. I am very proud of how our growing Kodiak community has continued to execute in the midst of the ongoing global pandemic,” said Victor Perlroth, MD, Chief Executive Officer of Kodiak. “There is a high unmet need

Business Is Booming for Dialysis Giant Fresenius. It Took a $137M Bailout Anyway.


As the coronavirus pandemic paralyzed most nonemergency medical practices this spring, the dialysis business, vital to the survival of patients with kidney disease, rolled ahead and in some cases grew.

Yet when the Trump administration sent billions in federal relief funds to medical organizations, at least $259 million went to dialysis providers, a KHN analysis of federal records found. Of that, kidney care behemoth Fresenius Medical Care accepted more than half, at least $137 million, despite acknowledging it had ample financial resources, the analysis showed.

The full amount going to Fresenius and many other dialysis providers is far higher than

Insurance Business Process Outsourcing (BPO) Market could be Worth 65880 million USD by 2026


The MarketWatch News Department was not involved in the creation of this content.

Aug 10, 2020 (Market Insight Reports) —
The Global Insurance Business Process Outsourcing (BPO) Market Research Report 2020-2026 offers an in-depth evaluation of each crucial aspect of the Global Insurance Business Process Outsourcing (BPO) industry that relates to market size, share, revenue, demand, sales volume, and development in the market. The report analyzes the Insurance Business Process Outsourcing (BPO) market over the values, historical pricing structure, and volume trends that make it easy to predict growth momentum and precisely estimate forthcoming opportunities in the Insurance Business Process